A7856
阿西莫司
≥99% (TLC)
别名:
2-羧基-5-甲基吡嗪4-氧化物, 5-甲基吡嗪羧酸4-氧化物
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C6H6N2O3
化学文摘社编号:
分子量:
154.12
MDL number:
UNSPSC Code:
12352205
EC Number:
256-928-3
NACRES:
NA.79
SMILES string
[n+]1(c(cncc1C(=O)O)C)[O-]
InChI key
DNRXJHATQULEHC-UHFFFAOYSA-N
InChI
1S/C6H6N2O3/c1-4-2-7-3-5(6(9)10)8(4)11/h2-3H,1H3,(H,9,10)
assay
≥99% (TLC)
form
powder
color
off-white to faint yellow
mp
177-180 °C
storage temp.
2-8°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
已经研究了烟酸衍生的血管舒张剂的降脂作用。
阿昔莫司又称氧甲吡嗪，是一种烟酸类似物。它可用作抗脂解药和血管扩张剂。阿西莫司可用于胰岛素和生长素释放肽相关的各种代谢研究。它可降低总胆固醇和总甘油三酯，从而有助于治疗高脂血症。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression
Cordido F, et al.
The Journal of clinical endocrinology and metabolism, 81(3), 914-918 (1996)
Mads Halbirk et al.
American journal of physiology. Heart and circulatory physiology, 299(4), H1220-H1225 (2010-08-17)
Circulating free fatty acids (FFAs) may worsen heart failure (HF) due to myocardial lipotoxicity and impaired energy generation. We studied cardiac and whole body effects of 28 days of suppression of circulating FFAs with acipimox in patients with chronic HF.
Fabrizio Montecucco et al.
American journal of physiology. Endocrinology and metabolism, 300(4), E681-E690 (2011-01-27)
Metabolic syndrome is a proatherosclerotic condition clustering cardiovascular risk factors, including glucose and lipid profile alterations. The pathophysiological mechanisms favoring atherosclerotic inflammation in the metabolic syndrome remain elusive. Here, we investigated the potential role of the antilipolytic drug acipimox on
B Salgin et al.
American journal of physiology. Endocrinology and metabolism, 296(3), E454-E461 (2008-12-25)
Normal beta-cells adjust their function to compensate for any decrease in insulin sensitivity. Our aim was to explore whether a prolonged fast would allow a study of the effects of changes in circulating free fatty acid (FFA) levels on insulin
Paola Lucidi et al.
Diabetes, 59(6), 1349-1357 (2010-03-20)
Changes in glucose metabolism occurring during counterregulation are, in part, mediated by increased plasma free fatty acids (FFAs), as a result of hypoglycemia-activated lipolysis. However, it is not known whether FFA plays a role in the development of posthypoglycemic insulin
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持